USC ALS Center of Excellence Clinical Trials

#	Disease Category	Title	ClinicalTrials.gov Status	ClinicalTrials.gov Link
1	ALS	Perpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen G: DNL343)	Completed	Click here
2	ALS	Perpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen F: ABBV-CLS-7262)	Completed	Click here
3	ALS	A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)	Recruiting	Click here
4	ALS	A prospective, multicenter, randomized, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)	Study is on hold	Click here
5	ALS	A Two-part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open Label Extension, Multicenter Study of the Efficacy and Safety of NurOwn in Participants with Amyotrophic Lateral Sclerosis	Not open for enrollment yet
6	ALS	A prospective, multicenter, randomized, double-blind, placebo-controlled, parallel groups, phase 3 trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from amyotrophic lateral sclerosis (ALS)	Not open for enrollment yet
7	ALS	Oxidative Markers and Efficacy in ALS /MND Phenotypes treated with Edaravone	Recruiting	Click here
8	ALS	Cellular re-programming to study neurodegenerative diseases, including ALS and FTD, using patient’s induced pluripotent stem cells		[Pending]
9	Myasthenia Gravis	A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open label extension phase(Novartis CLOU0644O12301)	Recruiting	Click here
10	Myasthenia Gravis	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis	Recruiting	Click here
11	Myasthenia Gravis	Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis (NIMBLE)	Enrollment is closed	Click here
12	CIDP	A Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathy	Recruiting	Click here
13	CIDP	A Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathy(MOBILIZE study)	Recruiting	Click here
14	CIDP	A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Active, not recruiting	Click here
15	CIDP	A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (VITALIZE study)	Recruiting	Click here
16	IIM	A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy	Enrollment is closed	Click here
17	IBM	An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis	Active, not recruiting	Click here
18	IBM	A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis	Active, not recruiting	Click here